ascend-1 and ascend-2: ceritinib for alk-rearranged nsclc and baseline brain metastases
Published 8 years ago • 79 plays • Length 1:23Download video MP4
Download video MP3
Similar videos
-
1:04
ascend-2 and ascend-3 trials: ceritinib in alk-rearranged nsclc with brain metastases
-
6:37
ascend-4: upfront ceritinib in alk-rearranged nsclc
-
5:15
results of ascend-4 trial of ceritinib versus chemotherapy in alk nsclc patients
-
5:19
ascend-5: ceritinib for alk positive nsclc previously treated with crizotinib
-
6:09
alk-positive nsclc: ascend-4 trial
-
2:44
ceritinib and brain metastases in nsclc
-
2:06
dr. alice t. shaw on ceritinib for frontline alk nsclc with brain metastases
-
5:52
ceritinib and alectinib in relapsed alk nsclc
-
3:57
ascend-8: safety data of ceritinib with or without food in nsclc
-
1:48
dr. chow on the use of ceritinib in alk nsclc metastatic to the brain
-
0:39
continuation of ceritinib beyond disease progression in alk-positive nsclc
-
11:38
debate: alk positive nsclc - front line therapy - ceritinib
-
6:47
upfront use of ceritinib in alk nsclc
-
5:21
ceritinib alternative dosing for alk nsclc
-
9:33
second-line brigatinib for alk/ros1-rearranged nsclc
-
2:43
dose escalation results of ceritinib and nivolumab for alk nsclc
-
2:00
ceritinib and other second generation alk inhibitors for acquired resistance in alk-positive nsclc
-
4:27
dose escalation results of ceritinib and nivolumab for alk nsclc
-
8:16
alta ii trial of brigatinib in alk-rearranged nsclc